(11) 98705-3426
TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

ABQURE

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: VerbalEscritório: US

Snapshot rápido

ABQURE

ST13

US500000090779841

Classe

5, 42, 44

Pedido

90779841

Registro

7102820

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

42

Atualização mais recente

12/06/2025

Classificação

Registrada

Tipo de marca

Verbal

Classes Nice

5, 42, 44

Data de depósito

17/06/2021

Data de registro

11/07/2023

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

11/07/2023

Última transação

12/06/2025

Escritório responsável

United States Patent and Trademark Office

Código da situação

700

Cadastro oficial

Principal Register

Fundamento do pedido

Intent to use, Foreign priority

Código do desenho

4

Tipo de titular

26

Localização do titular

AMSTERDAM, NL

Examinador

CHADAB, SETH

Unidade examinadora

L40

Localização atual

PUBLICATION AND ISSUE SECTION

Titulares e representantes

Titulares

UNIQURE BIOPHARMA B.V.
uniQure IP B.V.

Representantes

Julianne Abelman ABELMAN LAW PLLC

Classificação técnica

Classes Nice

Classe 5Classe 42Classe 44

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 5

Medicinal preparations for the diagnosistreatment or prevention of Central Nervous System diseasesLiver diseasesNeuromuscular diseases and Cardiovascular diseases; Viral systemsgene therapy systemsnucleic acid delivery systemsviral vectorsnon-viral vectorsgene therapy vectorsnucleic acid delivery vectorscells transformed by viral vectorsnon-viral vectorsgene therapy vectors or nucleic acid delivery vectors for medical purposesdrug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Pharmaceutical preparations and substances for the diagnosistreatment or prevention of Central Nervous System diseasesLiver diseasesNeuromuscular diseases and Cardiovascular diseases; clinical medical reagents for use in nucleic acid-based therapygene therapycell therapygene diagnosis and gene testingreagents for medical use; pharmaceutical preparationsvaccinesprophylaxis medicines and other pharmaceutical preparations all for use in nucleic acid-based therapygene therapy and cell therapy for the diagnosistreatment or prevention of Central Nervous System diseasesLiver diseasesNeuromuscular diseases and Cardiovascular diseases

Classe 42

Researchproduct development and consultancy in the field of biotechnologybiologic pharmaceutical preparationsmedical sciencechemistry and biochemistry; Research and product development in the field of pharmaceutics

Classe 44

Gene and nucleic acid deliverygene and nucleic acid transfergene and nucleic acid regulation and gene and nucleic acid modulation for the treatment of metabolic disordersocular disordersdiseases of the nervous systemblood disordersliver disordersmuscular disordersmuscular skeletal disorderscancersinfectious diseasesinflammatory and auto-immune diseasesvascular disordersinherited disordersgenetic disorders and single gene disorders; Consultancy in the field of pharmaceutics

Publicações

Histórico de despachos e eventos da marca no USPTO.

42 publicações encontradas

ASGN

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP

11/06/2025

EWAF

TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS

04/06/2025

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

04/06/2025

ECDR

TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS

04/06/2025

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

04/06/2025

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

04/06/2025

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

04/06/2025

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

04/06/2025

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

11/07/2023

R.PR

REGISTERED-PRINCIPAL REGISTER

11/07/2023

DP1B

1(B) BASIS DELETED; PROCEED TO REGISTRATION

08/06/2023

AITU

CASE ASSIGNED TO INTENT TO USE PARALEGAL

01/06/2023

IUCN

NOTICE OF ALLOWANCE CANCELLED

14/04/2023

D1BR

TEAS DELETE 1(B) BASIS RECEIVED

14/04/2023

NOAM

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

11/04/2023

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

14/02/2023

PUBO

PUBLISHED FOR OPPOSITION

14/02/2023

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

25/01/2023

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

12/01/2023

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

09/01/2023

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

09/01/2023

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

09/01/2023

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

14/11/2022

GNRT

NON-FINAL ACTION E-MAILED

14/11/2022

CNRT

NON-FINAL ACTION WRITTEN

14/11/2022

ZZZX

PREVIOUS ALLOWANCE COUNT WITHDRAWN

03/11/2022

PBCR

WITHDRAWN FROM PUB - OG REVIEW QUERY

20/09/2022

FIXD

ELECTRONIC RECORD REVIEW COMPLETE

07/09/2022

ERRR

ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED

02/09/2022

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

30/08/2022

RCCK

SUSPENSION CHECKED - TO ATTORNEY FOR ACTION

10/08/2022

ERSI

TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED

26/07/2022

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

20/07/2022

ECDR

TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS

20/07/2022

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

20/07/2022

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

20/07/2022

GNS3

NOTIFICATION OF LETTER OF SUSPENSION E-MAILED

10/02/2022

GNSL

LETTER OF SUSPENSION E-MAILED

10/02/2022

CNSL

SUSPENSION LETTER WRITTEN

10/02/2022

DOCK

ASSIGNED TO EXAMINER

08/02/2022

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

03/09/2021

NWAP

NEW APPLICATION ENTERED

21/06/2021

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace ABQURE ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.